선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Centene Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $31.1B | |
|---|---|---|
| P/E (forward) | 11.2x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $117.98B | $135.48B | $140.10B | $145.51B | $174.58B | +10.3% |
| Gross profit | $14.49B | $16.92B | $17.64B | $17.07B | $14.21B | -0.5% |
| Operating income | $1.78B | $1.32B | $2.93B | $3.18B | $-7.62B | — |
| Net income | $1.35B | $1.20B | $2.70B | $3.31B | $-6.67B | — |
| EPS (diluted) | $2.28 | $2.07 | $4.95 | $6.31 | $-13.53 | — |
| EBITDA | $3.81B | $4.06B | $2.93B | $6.20B | $-5.14B | — |
| R&D | — | — | — | — | — | — |
| SG&A | $9.60B | $11.59B | $12.56B | $12.40B | $12.90B | +7.7% |
Recent company headlines from major financial publishers.
The base scenario represents the modal operating path with a target of $51.46 and an assigned probability of 55.0%, implying an expected return of -18.3% relative to $62.99. In this scenario, Centene successfully stabilizes its core Medicaid business as post-redetermination member attrition concludes and state actuarial rate adjustments gradually align with medical cost trends. Commercial Marketplace operations deliver pretax margins within the guided range, supported by positive risk-adjustment transfers. Overhead streamlining initiatives lower administrative expense ratios, supporting normalized operating margins and driving diluted earnings per share toward consensus expectations over the forecast horizon. Investors would confirm this path through consecutive quarters of stable medical loss ratios and realized administrative cost efficiencies.
The bull scenario outlines an accelerated recovery path toward Potential value of $59.33, reflecting a target of $59.33 and a probability of 20.0%, delivering a potential return of -5.8% from $62.99. This outcome requires state Medicaid rate increases to exceed medical inflation, fully restoring underwriting profitability across the core portfolio. Concurrently, favorable risk-adjustment determinations lift Commercial Marketplace margins beyond guided expectations, while enterprise overhead streamlining generates structural administrative cost reductions above initial targets. Robust cash conversion accelerates debt paydown, de-risking upcoming maturities and prompting market multiple expansion toward leading managed care peers. Disconfirmation would occur if state rate updates fail to exceed trend or exchange competition erodes pricing power.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.4% | $53.3 | $53.3 | $53.3 | $53.3 | $53.3 |
| 8.9% | $52.2 | $52.2 | $52.2 | $52.2 | $52.2 |
| 9.4% | $51.5 | $51.5 | $51.5 | $51.5 | $51.5 |
| 9.9% | $50.2 | $50.2 | $50.2 | $50.2 | $50.2 |
| 10.4% | $49.3 | $49.3 | $49.3 | $49.3 | $49.3 |
Upcoming earnings date and setup when available.
매월 발행된 리서치 판이 부여한 등급입니다. 등급은 분석 시점의 가격을 공정 가치와 비교한 것이며, 판단이 맞았는지에 대한 기록이 아닙니다.
| 연도 | 1월 | 2월 | 3월 | 4월 | 5월 | 6월 | 7월 | 8월 | 9월 | 10월 | 11월 | 12월 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |